Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000905718-18-000123
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-12 16:09:09
Reporting Period:
2017-07-19
Accepted Time:
2018-02-12 16:09:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1042074 Cymabay Therapeutics Inc. CBAY Pharmaceutical Preparations (2834) 943103561
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1252524 Von Kurt Emster C/o Cymabay Therapeutics, Inc.
7999 Gateway Blvd, Suite 130
Newark CA 94560
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-07-19 153,846 $6.50 1,753,846 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 90,000 Direct
Common Stock 17,236 Indirect By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Footnotes
  1. Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI, LP's ("ABV VI") July 19, 2017 purchase of 153,846 shares of common stock of CymaBay Therapeutics, Inc. ("Issuer") at a price of $6.50 per share reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in the sales of common stock by ABV VI and Abingworth BioEquities Master Fund Limited ("ABE") made between September 28, 2017 and January 17, 2018. The Reporting Person has paid to Issuer $692.00, representing the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar).
  2. These shares were omitted from the Forms 4 filed by Reporting Person on October 2, 2017 and the twelve Form 4 filings made thereafter.
  3. The shares purchased are held by ABV VI. Abingworth LLP ("Abingworth") is the investment manager of ABV VI and ABE (the "Abingworth Funds") and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth.
  4. From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.